Benitec Biopharma (BNTC) Common Equity (2019 - 2025)
Benitec Biopharma has reported Common Equity over the past 7 years, most recently at $187.4 million for Q4 2025.
- Quarterly results put Common Equity at $187.4 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $187.4 million (changed N/A YoY), and the annual figure for FY2025 was $97.3 million, up 105.92%.
- Common Equity reached $187.4 million in Q4 2025 per BNTC's latest filing, up from $93.6 million in the prior quarter.
- Across five years, Common Equity topped out at $187.4 million in Q4 2025 and bottomed at -$219.4 million in Q1 2025.
- Median Common Equity over the past 5 years was $11.5 million (2024), compared with a mean of $18.5 million.
- The largest annual shift saw Common Equity surged 23290.1% in 2024 before it tumbled 2007.57% in 2025.
- Over 5 years, Common Equity stood at $10.8 million in 2021, then dropped by 17.0% to $9.0 million in 2022, then surged by 72.0% to $15.5 million in 2023, then crashed by 106.42% to -$993000.0 in 2024, then skyrocketed by 18968.18% to $187.4 million in 2025.
- Business Quant data shows Common Equity for BNTC at $187.4 million in Q4 2025, $93.6 million in Q3 2025, and $97.3 million in Q2 2025.